MemorialCare Heart & Vascular Institute (MHVI), through its advanced research program, is participating in a CSL Behring-sponsored multi-center, Phase III clinical trial – "ApoA-I Event reducinG in Ischemic Syndromes II (AEGIS-II) – which is studying the removal of cholesterol from the arteries to reduce the risk of a second heart attack or stroke in patients.
News | Heart Failure
MemorialCare Heart and Vascular Institute Participating in Global Study of CSL112 in Patients with Acute Coronary Syndrome (AEGIS-II)
March 8, 2022 – MemorialCare Heart & Vascular Institute (MHVI), through its advanced research program, is participating ...
Home March 08, 2022
Home
James de Lemos, M.D.
News | Heart Failure
Addressing the Difficulty of Diagnosing Heart Attacks After Heart Surgery
Mrach 8, 2022 – Diagnosing heart attacks after heart surgery remains difficult due to shortcomings of current diagnostic ...
Home March 08, 2022
Home
AdvaMed is saddened to share that a beloved member of the AdvaMed family, Wendy Siminski, Senior Vice President of Conferences and Events, has passed away after a brave battle with breast cancer.
News | Cardiovascular Business
AdvaMed Mourns the Passing of Wendy Siminski

March 7, 2022 — AdvaMed is saddened to share that a beloved member of the AdvaMed family, Wendy Siminski, Senior Vice ...

Home March 07, 2022
Home
In January, The University of Maryland School of Medicine (UMSOM) and the University of Maryland Medical Center (UMMC) successfully executed a groundbreaking porcine heart transplant procedure in a human. This was the first successful transplant of a genetically modified pig’s heart into a human patient.
Feature | Cardiovascular Business | By Melinda Taschetta-Millane
DAIC’s Top 10 for the Month of February

Here is what you and your colleagues found to be most interesting in the field of cardiology during the month of ...

Home March 04, 2022
Home
NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases, today announced dose administration for the first patient in its PREVAIL study, a global Phase 3 cardiovascular outcomes trial of the novel cholesteryl ester transfer protein (CETP) inhibitor obicetrapib
News | Heart Failure
NewAmsterdam Pharma Doses First Patient in its PREVAIL Study
March 4, 2022 – NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of ...
Home March 04, 2022
Home
CIRCA S-CATH M esophageal temperature probe
News | EP Mapping and Imaging Systems
CIRCA Scientific Receives FDA Clearance for New Esophageal Temperature Probe

March 3, 2022 – CIRCA Scientific, Inc. has announced that its S-CATH M Esophageal Temperature Probe is now cleared for ...

Home March 03, 2022
Home
Spontaneous coronary artery dissection (SCAD), a tear in an artery supplying blood to the heart, is a common cause of serious or fatal heart attacks that occur in women under age 50.
News | Heart Failure
Common Cause of Heart Attacks in Younger Adults Linked to Gene Variants
March 3, 2022 – Spontaneous coronary artery dissection (SCAD), a tear in an artery supplying blood to the heart, is a ...
Home March 03, 2022
Home
The University of Maryland School of Medicine’s Institute of Human Virology, a Global Virus Network (GVN) Center of Excellence, physician researchers played a collaborative role in last month’s successful transplant of a genetically-modified pig heart into a patient with terminal heart disease by creating pathogen surveillance strategies and developing an infection prevention strategy for this unprecedent significant medical advancement.
News | Heart Failure
Experts Perform Pathogen Surveillance for Unprecedented Pig-to-Human Heart Transplant
March 3, 2022 – The University of Maryland School of Medicine’s Institute of Human Virology, a Global Virus Network (GVN ...
Home March 03, 2022
Home
As 1-year-old SaRyia Moore and her family celebrate American Heart Month, they do so will full, grateful hearts — including SaRyia's transplanted heart she received just eight weeks ago, saving her young life.
News | Pediatric Cardiology
Texas Children's Hospital Passes Milestones of More Than 500 Heart Transplants, 2,000 Solid Organ Transplants
March 2, 2022 – As 1-year-old SaRyia Moore and her family celebrate American Heart Month, they do so will full, grateful ...
Home March 02, 2022
Home
John Farquhar
News | Cardiovascular Business
HeartFlow Announces CEO Transition

March 2, 2022 – HeartFlow, Inc. has announced that John Farquhar has been appointed President and Chief Executive ...

Home March 02, 2022
Home
An international study led by a researcher from Tel Aviv University offers a novel technology that can assist many patients implanted with bioprosthetic heart valve by avoiding additional complicated replacement surgery.
News | Heart Valve Technology
Novel Technology Could Prevent Repeat Operations to Replace a Faulty Bioprosthetic Heart Valve
March 2, 2022 – An international study led by a researcher from Tel Aviv University offers a novel technology that can ...
Home March 02, 2022
Home
Students and faculty
News | Cardiovascular Education
Harding University Offering Nation's First Master of Science in Cardiac Function and Interventional Technology Program
March 1, 2022 – To meet the growing industry demand for highly trained clinical professionals specializing in cardiac ...
Home March 01, 2022
Home
The same thing can be said for a heart with mitral valve prolapse (MVP) — as the diseased valve enlarges, the cords connected to the heart tissue feel stress and respond accordingly with stiffness and scarring, according to a recent paper in the Journal of the American Heart Association. 
News | Heart Failure
Earlier Surgical Intervention Could Stave Off Fibrosis in People with Mitral Valve Prolapse

March 1, 2022 – The larger the sail, the more wind it catches. But as that size increases, so does the stress ...

Home March 01, 2022
Home
Anand Chockalingam
News | Heart Failure
Adolescent Psychological Well-being Tied to Adult Risk of Cardiovascular Disease, Study Finds
March 1, 2022 – Scientists have known for years that a person’s risk of cardiovascular disease (CVD) can be lowered with ...
Home March 01, 2022
Home
A new report says the wearable healthcare devices market is anticipated to grow at a CAGR of 13% from $16 billion in 2021 to $61 billion by 2032.
News | Wearables
Wearable Healthcare Devices Market to Value $61 Billion by 2032
March 1, 2022 – A new report says the wearable healthcare devices market is anticipated to grow at a CAGR of 13% from ...
Home March 01, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now